Catabasis Pharmaceuticals Financials

Catabasis Pharmaceuticals Stock Summary

Catabasis Pharmaceuticals competes with Pintec Technology, Gerdau SA, Univest Pennsylvania, Mill City, and Discover Financial. Catabasis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics in the United States. The company was incorporated in 2008 and is based in Boston, Massachusetts. Catabasis Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.

Catabasis Pharmaceuticals Key Financial Ratios

Generally speaking, Catabasis Pharmaceuticals' financial ratios allow both analysts and investors to convert raw data from Catabasis Pharmaceuticals' financial statements into concise, actionable information that can be used to evaluate the performance of Catabasis Pharmaceuticals over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Catabasis Pharmaceuticals reports annually and quarterly.

Catabasis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Catabasis Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Catabasis Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Catabasis Pharmaceuticals competition to find correlations between indicators driving Catabasis Pharmaceuticals's intrinsic value. More Info.Catabasis Pharmaceuticals is number one stock in return on equity category among related companies. It is number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Catabasis Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Catabasis Pharmaceuticals' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Catabasis Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

If you are still planning to invest in Catabasis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Catabasis Pharmaceuticals' history and understand the potential risks before investing.